为探讨 AML 非强化治疗中出现可靶向克隆时的策略、MRD 检测应用等问题，研究人员分析相关疗法及生存数据。发现 Ven-Aza 序贯治疗或三联疗法可优化方案，MRD 检测仍需完善，AML 生存率显著提升。研究为临床提供方向。 急性髓系 ...

flt3-itd突变影响约30%的aml患者，比野生型flt3有更高的复发风险且整体生存期更短。 FLT3-TKD突变则影响约7%的AML患者。 在AML治疗过程中，甚至在复发后 ...

为了揭示aml中异常染色质开放性产生的调控分子，研究人员利用crispr筛选发现，染色质重塑蛋白smarca5是介导aml中异常染色质开放性的关键蛋白，并综合利用数据库挖掘、临床病人样本分析、条件性敲除小鼠构建等一系列技术手段发现，smarca5在aml病人中高表达，且与预后不良相关；功能上，smarca5能够 ...

Despite decades of studies on the molecular pathogenesis of acute myeloid leukaemia (AML), the mutations that contribute to the pathogenesis of the disease were still not completely defined, and ...

Alternative genetic pathways were previously outlined in the pathogenesis of therapy-related myelodysplasia (t-MDS) and acute myeloid leukemia (t-AML) based on cytogenetic characteristics. Some of ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response ...

Panelists report that the AUGMENT-101 trial demonstrated meaningful clinical benefits of menin inhibitors in ...

People with a third copy of chromosome 21, known as trisomy 21, are at high risk of developing acute myeloid leukemia (AML), an aggressive form of blood cancer. Scientists have now identified the ...

Understanding the fundamental molecular mechanisms underlying normal hematopoiesis and AML pathogenesis can aid the development of novel and effective targeted therapies.

Disruption of normal ‘hematopoietic’ development or the differentiation of stem cells into various blood types, can result in blood cancers like acute myeloid leukemia (AML). Despite ...

TransCure bioServices has developed cell line-derived xenograft (CDX) mouse models that will change how researchers tackle the preclinical studies of cancer therapies to treat acute myeloid leukemia ...